Prophylactic HIV Drugs Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR (2024 - 2029) | 4.10 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Prophylactic HIV Drugs Market Analysis
The Prophylactic HIV Drugs Market is expected to register a CAGR of 4.10% during the forecast period.
The market is expected to grow owing to factors such as the high prevalence of HIV cases, increasing government initiatives, and increasing research and development activities. In addition, growing awareness of HIV prevention is also expected to drive the market growth over the forecast period. The high burden of new and existing HIV cases is expected to boost the market growth over the study period.
For instance, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS) factsheet 2023, in 2022, 51 thousand new HIV infections were reported compared to 48 thousand new cases in previous years. Similarly, as per the same source, the number of people living with HIV in Brazil was reported to be 990 thousand in 2022. This shows the significantly high burden of HIV, which is expected to increase the need for prophylactic HIV drugs to prevent spread and is likely to propel the market growth over the forecast period.
A large number of non-profit and government organizations are initiating various programs or studies to prevent HIV through various products, which is likely to propel the growth of the market. For instance, in April 2024, the CATALYST study of the United States Agency for International Development (USAID) expanded HIV prevention options for women and girls in Africa. This study provides complete information on and access to three biomedical HIV prevention methods, which include daily oral pre-exposure prophylaxis (PrEP) and newly-introduced injectable cabotegravir for PrEP (CAB PrEP) and others. Hence, government initiatives to provide awareness on the prevention of HIV are expected to drive market growth over the study period.
In addition, product developments, launches, and approval by regulatory authorities are expected to support market expansion over the forecast period. For instance, in October 2023, Gilead Sciences Inc. reported the phase 2 clinical trial to evaluate an investigational long-acting HIV prevention option in Europe. The study assesses the persistence of lenacapavir compared with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in people who benefit from pre-exposure prophylaxis (PrEP). Thus, such efforts by market participants may result in the launch of advanced preventive therapy, which is expected to boost market growth over the forecast period.
However, lower penetration in an underdeveloped market and side effects of this drug, such as vomiting, nausea, tiredness, and diarrhea, are expected to restrain the market's growth over the forecast period.
Prophylactic HIV Drugs Market Trends
The Oral Drug Forms Segment is Expected to Hold a Significant Share During the Forecast Period
The oral drug segment is expected to dominate the global prophylactic HIV drug market over the forecast period. This can be attributed to new product development, the presence of a strong pipeline, and rising product approvals. The oral route also has several pharmacokinetic advantages, such as a higher rate of bioavailability, rapid drug delivery, and high efficacy. All these advantages are expected to propel segment growth.
The oral route is the most patient-compliant and, therefore, is the most widely adopted by patients. The development of promising new drugs and potential clinical pipeline candidates are some of the major factors that are expected to drive segment growth. For instance, according to a study presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine were found to be safe for HIV prevention among women. Hence, the new studies help increase the applications of drugs for the prevention of HIV and are likely to propel the segment growth over the forecast period.
The market's future growth is anticipated to be fueled by the approval and launch of various potential drug candidates. For instance, in September 2023, GSK PLC and ViiV Healthcare, with Pfizer and Shionogi as shareholders, received approval from the European Commission for Apretude (cabotegravir long-acting (LA) injectable and tablets) for HIV prevention. Thus, new research studies and approval of oral drugs are expected to boost segment growth over the forecast period.
North America is Expected to Hold a Significant Market Share During the Forecast Period
North America is one of the most vital regions and a significant revenue contributor to the global HIV prophylactic drug market. Heightened patient awareness of disease-remitting therapies, a technologically advanced healthcare framework, and supportive reimbursement policies stimulate the region's growth.
For instance, as per the data published by the Centers for Disease Control and Prevention in May 2024, 38,000 people received an HIV diagnosis in the United States in 2022, which was an increase of 5% compared to 2021 due to post-pandemic effects on the public health system. Similarly, according to the 2022 surveillance highlights, over 1,833 new HIV cases were reported in Canada, 4.7 per 100,000 population in 2022. Thus, the growing prevalence of HIV, along with the high burden of new HIV cases in the region, is expected to propel the growth of the market over the forecast period.
In addition, increasing government funding and programs for HIV prevention and treatment are expected to boost the market growth over the forecast period. For instance, for the fiscal year 2023, the US government's spending on the domestic fight against HIV increased to more than USD 28 billion annually. This sum includes discretionary and required spending for Medicare, Medicaid, Social Security payouts, and other expenditures needed.
Furthermore, the region's new product approvals and launches are expected to boost market growth. For instance, in May 2024, ViiV Healthcare received approval from Health Canada for APRETUDE (cabotegravir tablets and extended-release injectable suspension) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at-risk individuals who are HIV-1 negative. Hence, these approvals increase the availability of prophylactic HIV drugs in the region, propelling the market growth.
Hence, due to the high burden of HIV infections, increasing government funding, and new product approvals, the market is expected to witness growth in North America.
Prophylactic HIV Drugs Industry Overview
The prophylactic HIV drug market is fragmented, with several players. Companies invest heavily in research and development to create novel drugs with improved efficacy, safety profiles, and delivery mechanisms. In addition, the companies are expanding into new geographical markets through partnerships or direct market entry strategies that tap into growing demand and diversified revenue streams. Some prominent market participants are Bristol-Myers Squibb Company, Cipla Inc., Johnson & Johnson, Viatris Inc. (Mylan), and Merck & Co. Inc.
Prophylactic HIV Drugs Market Leaders
-
Merck & Co., Inc.
-
Cipla Inc
-
Bristol-Myers Squibb Company
-
Viatris Inc. (Mylan)
-
Johnson & Johnson
*Disclaimer: Major Players sorted in no particular order
Prophylactic HIV Drugs Market News
- June 2024: Gilead Sciences Inc. funded two studies on long-acting human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) through the HIV Prevention Trials Network (HPTN). The studies focuses on a long-acting version of lenacapavir administered every six months.
- March 2024: ViiV Healthcare reported the positive findings from its phase I study of an investigational formulation of cabotegravir, known as cabotegravir ultra long-acting (CAB-ULA), which can be dosed at intervals of at least four months.
Prophylactic HIV Drugs Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 High Prevalence of HIV/AIDS
- 4.2.2 Increasing Government Initiatives
- 4.2.3 Increasing R&D Activities
-
4.3 Market Restraints
- 4.3.1 Lower Penetration in Underdeveloped Markets
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Drug
- 5.1.1 Tenofovir
- 5.1.2 Emtricitabine
- 5.1.3 Other Drugs
-
5.2 By Dosage Form
- 5.2.1 Oral
- 5.2.2 Topical
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 AbbVie
- 6.1.2 SK Capital (APOTEX INC.)
- 6.1.3 Boehringer Ingelheim International GmbH
- 6.1.4 Bristol-Myers Squibb Company
- 6.1.5 Cipla Inc.
- 6.1.6 F. Hoffmann-La Roche AG (Genentech Inc.)
- 6.1.7 Gilead Sciences Inc.
- 6.1.8 Johnson & Johnson
- 6.1.9 Merck & Co. Inc.
- 6.1.10 Viatris Inc. (Mylan)
- 6.1.11 Pfizer Inc.
- 6.1.12 Teva Pharmaceutical Industries Ltd
- 6.1.13 GSK PLC (ViiV Healthcare Group of Companies)
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityProphylactic HIV Drugs Industry Segmentation
As per the scope of the report, human immunodeficiency virus (HIV) is a chronic and life-threatening disease. The disease can be transferred from one person to another through blood-to-blood or sexual contact. HIV prophylactic drugs are the medication that is given to prevent HIV disease before it even occurs.
The prophylactic HIV drugs market is segmented by drug, dosage form, and geography. By drug, the market is segmented into tenofovir, emtricitabine, and other drugs. The other drugs category includes cabotegravir, lenacapavir, and others. By dosage form, the market is segmented into oral and topical. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the market sizes and forecasts in terms of value (USD) for the above segments.
| By Drug | Tenofovir | |
| Emtricitabine | ||
| Other Drugs | ||
| By Dosage Form | Oral | |
| Topical | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Prophylactic HIV Drugs Market Research FAQs
What is the current Prophylactic HIV Drugs Market size?
The Prophylactic HIV Drugs Market is projected to register a CAGR of 4.10% during the forecast period (2024-2029)
Who are the key players in Prophylactic HIV Drugs Market?
Merck & Co., Inc., Cipla Inc, Bristol-Myers Squibb Company, Viatris Inc. (Mylan) and Johnson & Johnson are the major companies operating in the Prophylactic HIV Drugs Market.
Which is the fastest growing region in Prophylactic HIV Drugs Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Prophylactic HIV Drugs Market?
In 2024, the North America accounts for the largest market share in Prophylactic HIV Drugs Market.
What years does this Prophylactic HIV Drugs Market cover?
The report covers the Prophylactic HIV Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Prophylactic HIV Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Prophylactic HIV Drugs Industry Report
Statistics for the 2024 Prophylactic HIV Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Prophylactic HIV Drugs analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
